Abstract
The TH17 helper cells of the immune system have a dark side: they mediate autoimmune disorders. Two drugs that prevent the differentiation and activity of these cells might be of therapeutic value.
MeSH terms
-
Animals
-
Autoimmune Diseases / drug therapy
-
Autoimmune Diseases / immunology
-
Autoimmune Diseases / pathology
-
Autoimmunity / drug effects
-
Autoimmunity / immunology
-
Cell Differentiation / drug effects*
-
Digoxin / analogs & derivatives
-
Digoxin / metabolism
-
Digoxin / pharmacology*
-
Digoxin / therapeutic use
-
Interleukin-17 / biosynthesis
-
Interleukin-17 / immunology
-
Interleukin-17 / metabolism
-
Mice
-
Nuclear Receptor Subfamily 1, Group F, Member 1 / antagonists & inhibitors*
-
Nuclear Receptor Subfamily 1, Group F, Member 1 / metabolism
-
Nuclear Receptor Subfamily 1, Group F, Member 3 / antagonists & inhibitors*
-
Nuclear Receptor Subfamily 1, Group F, Member 3 / metabolism
-
Sulfonamides / pharmacology*
-
Th17 Cells / cytology*
-
Th17 Cells / drug effects*
-
Th17 Cells / immunology
-
Th17 Cells / metabolism
-
Thiazoles / pharmacology*
Substances
-
Interleukin-17
-
Nuclear Receptor Subfamily 1, Group F, Member 1
-
Nuclear Receptor Subfamily 1, Group F, Member 3
-
Rora protein, mouse
-
SR1001
-
Sulfonamides
-
Thiazoles
-
Digoxin